#1 Clinical Trials Search in Europe

Paraffin White Soft

Paraffin White Soft, a common ingredient in moisturizers, is being studied in clinical trials for its potential benefits in treating and preventing atopic dermatitis, especially in children. These trials aim to evaluate the effectiveness of moisturizers containing Paraffin White Soft in managing eczema symptoms, preventing relapses, and potentially preventing the onset of atopic dermatitis in high-risk infants. The studies focus on the drug’s ability to improve skin hydration, reduce inflammation, and maintain skin barrier function in patients with this chronic skin condition.

Table of Contents

What is Paraffin White Soft?

Paraffin White Soft, also known as soft white paraffin or white petrolatum, is a common ingredient in moisturizing creams and ointments. It is often combined with liquid paraffin to create emollient products[1]. These substances are used in skincare products to help moisturize and protect the skin.

Medical Uses

Paraffin White Soft is primarily used in the treatment and management of dry skin conditions, particularly atopic dermatitis (also known as eczema). Atopic dermatitis is a chronic, itchy skin condition that often affects children but can persist into adulthood[1].

Effectiveness in Treating Atopic Dermatitis

Clinical trials are being conducted to evaluate the effectiveness of moisturizers containing Paraffin White Soft in treating and preventing atopic dermatitis. One study aims to demonstrate the superiority of a newly developed moisturizer in preventing eczema relapse in children with atopic dermatitis compared to a reference cream[1].

Another study is investigating the potential of a moisturizing barrier-stabilizing skin cream containing Paraffin White Soft in preventing the development of atopic dermatitis symptoms in high-risk children[2]. This research focuses on the cream’s ability to reduce the cumulative incidence of atopic dermatitis in infants with a high familial risk of the condition.

Application and Dosage

The application of Paraffin White Soft-containing products varies depending on the specific formulation and the patient’s needs. In clinical trials, the maximum daily dose ranged from 12 to 18 ml or grams, with treatment periods lasting up to 6-13 months[1][2]. However, it’s important to note that these dosages are specific to the studies and may not reflect general usage recommendations.

Potential Benefits

The use of moisturizers containing Paraffin White Soft may offer several potential benefits for individuals with atopic dermatitis:

  • Prevention of eczema relapse
  • Reduction in disease severity
  • Improvement in quality of life
  • Possible delay or prevention of atopic dermatitis onset in high-risk infants

Safety and Side Effects

Paraffin White Soft is generally considered safe for topical use. However, as with any medical treatment, there may be potential side effects or adverse reactions. Clinical trials are assessing the tolerability and safety of products containing this ingredient[1]. It’s important to consult with a healthcare provider before starting any new treatment regimen, especially for children or individuals with sensitive skin.

Ongoing Research

Current clinical trials are investigating various aspects of Paraffin White Soft-containing moisturizers, including:

  • Their effect on preventing eczema relapse in children
  • The potential to prevent atopic dermatitis symptoms in high-risk infants
  • Impact on disease severity and quality of life
  • Effects on skin microbiome
  • Relationship between treatment effects and genetic factors (such as filaggrin gene mutations)

These studies aim to provide more comprehensive data on the efficacy and safety of Paraffin White Soft in managing and preventing atopic dermatitis[1][2].

Aspect Details
Study Drug Paraffin White Soft (in combination with other ingredients)
Target Condition Atopic Dermatitis (Eczema)
Study Populations Children 2-12 years old with mild to moderate AD; Newborns <3 weeks with high familial AD risk
Primary Objectives Prevent eczema relapse; Prevent AD onset in high-risk infants
Key Measurements SCORAD, Quality of Life, Time to relapse, Cumulative AD incidence
Study Duration 6-12 months
Application Method Topical (applied to skin)
Additional Assessments Skin microbiome, Genetic factors (FLG mutations), Allergen sensitization

FAQ

  • What is Paraffin White Soft and how is it used in these clinical trials? Paraffin White Soft is a moisturizing ingredient used in creams and ointments. In these clinical trials, it's being studied as part of moisturizing formulations to treat and prevent atopic dermatitis, particularly in children. The trials are testing its effectiveness in preventing eczema relapses and potentially preventing the onset of atopic dermatitis in high-risk infants.
  • Who are the target participants for these clinical trials? The trials focus on different age groups. One study includes children aged 2-12 years with mild to moderate atopic dermatitis. Another study targets newborns less than 3 weeks old who have a high familial risk of developing atopic dermatitis. Both studies aim to evaluate the effectiveness of moisturizers containing Paraffin White Soft in managing or preventing eczema symptoms.
  • What are the main objectives of these clinical trials? The main objectives include demonstrating the superiority of newly developed moisturizers in preventing eczema relapse compared to reference creams, evaluating the effect on disease severity, assessing quality of life improvements, and investigating the potential of early moisturizer use in preventing the onset of atopic dermatitis in high-risk infants.
  • How long do these clinical trials last? The duration varies between the trials. One study lasts up to 6 months, while another follows infants for up to 12 months. These timeframes allow researchers to observe long-term effects and track the development or prevention of atopic dermatitis symptoms over time.
  • What are some of the key measurements used in these trials? The trials use various measurements including the SCORAD (SCORing Atopic Dermatitis) index to assess disease severity, quality of life questionnaires, time to relapse, cumulative incidence of atopic dermatitis, and frequency of sensitization to allergens. They also monitor adverse events, compliance with treatment, and in some cases, explore genetic factors and skin microbiome changes.

Ongoing Clinical Trials on Paraffin White Soft

  • Study on Preventing Atopic Dermatitis in High-Risk Children Using Paraffin White Soft Cream

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Sweden

Glossary

  • Atopic Dermatitis (AD): A chronic inflammatory skin condition characterized by itchy, red, swollen, and cracked skin. It's also known as eczema and is common in children.
  • SCORAD: SCORing Atopic Dermatitis, a tool used to assess the extent and severity of eczema. It considers the area of skin involved, intensity of symptoms, and subjective symptoms like itching and sleep loss.
  • Relapse: The return or worsening of disease symptoms after a period of improvement. In atopic dermatitis, it refers to the recurrence of eczema flare-ups.
  • Emollient: A moisturizing treatment applied directly to the skin to soothe and hydrate it. Paraffin White Soft is an example of an emollient.
  • Xerosis: Abnormally dry skin, which is a common feature of atopic dermatitis.
  • Sensitization: The process by which the immune system becomes hypersensitive to a particular substance, such as an allergen.
  • IgE: Immunoglobulin E, an antibody that plays a crucial role in allergic responses and is often elevated in individuals with atopic conditions.
  • Microbiome: The collection of microorganisms that live on and in the human body, including on the skin. Changes in the skin microbiome may be associated with atopic dermatitis.
  • FLG gene: The gene responsible for producing filaggrin, a protein important for maintaining the skin barrier. Mutations in this gene are associated with an increased risk of atopic dermatitis.
  • Topical application: Administration of a medication or treatment directly onto the skin.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effect-of-a-new-moisturiser-with-paraffin-and-liquid-paraffin-on-preventing-eczema-relapse-in-children/
  2. http://clinicaltrials.eu/trial-id/2024-513289-21-00